A Novel Vaccine Against Mosquito Saliva

In a phase I study, a mosquito saliva peptide–based vaccine was well-tolerated, and when administered with an adjuvant immune modulator, it was immunogenic.

Mosquito saliva contains multiple immunomodulatory molecules; some appear to enhance infectivity of pathogens and potentiate transmission. Might a vaccine against mosquito saliva reduce transmission of mosquito-borne pathogens?

To explore that possibility, investigators conducted a randomized, double-blind, placebo-controlled, phase I trial to test the safety and immunogenicity of a vaccine (AGS-v) created from a cocktail of synthetic peptides from the saliva of Anopheles gambiae (malaria vector) mosquitoes, selecting peptides also found in Aedes spp. and Culex spp. mosquitoes. Among 49 healthy study participants (median age, 30.5), 16 received AGS-v, 17 received AGS-v plus an adjuvant immune modulator (Montanide ISA 51), and 16 received ste…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

A Novel Vaccine Against Mosquito Saliva

Topics

Reviewing Author